Eiger BioPharmaceuticals doses first patients with Lambda in COVID-19 trial
Eiger BioPharmaceuticals said that it has dosed the first patients in a phase 2 trial of its hepatitis delta virus drug candidate peginterferon lambda (Lambda) in outpatients at the Stanford University School of Medicine having mild COVID-19. The California-based biopharma company said that nearly 120 patients will be randomly grouped in a 1:1 ratio to […]